scholarly journals Analysis of Peanut Allergen Components Sensitization and Cross Reaction with Pollen Allergen in Chinese Southerners with Allergic Rhinitis and/or Asthma

2021 ◽  
Vol Volume 14 ◽  
pp. 1285-1293
Author(s):  
Wenting Luo ◽  
Shuwen Yang ◽  
Huimin Huang ◽  
Liting Wu ◽  
Zhangkai J Cheng ◽  
...  
2020 ◽  
Vol 41 (3) ◽  
pp. 183-191
Author(s):  
Krzysztof Kowal ◽  
Agnieszka Pampuch ◽  
Ewa Sacharzewska ◽  
Ewa Swiebocka ◽  
Zenon Siergiejko ◽  
...  

Background: The presence of immunoglobulin E (IgE), which cross-reacts with allergen components, such as profilins, polcalcins, and cross-reacting carbohydrate determinants (CCD), creates a problem when selecting patients for allergen immunotherapy by using conventional methods. The aim of this study was to evaluate the prevalence of sensitization to profilins, polcalcins, and CCDs in patients with seasonal pollen allergic rhinitis. Methods: The study was performed on a group of 112 patients with seasonal pollen allergic rhinitis, ages 14 to 55 years, with sensitization to at least one seasonal allergen (IgE > 0.7 kUA/L). The presence of IgE sensitization to recombinant (r) Bet v 2, rPhl p 12, rBet v 4, rPhl p 7, and CCDs, in addition to rBet v 1, rPhl p 1, rPhl p 5, was evaluated by using a multiparameter immunoblot. Results: Among the studied patients, 64.3, 80.4, and 41.1% were sensitized to birch, timothy grass, and mugwort pollen, respectively. Sensitization to profilins rBet v 2/Phl p 12 was demonstrated in 28.6%, to polcalcins Bet v 4/Phl p 7 in 8.9%, and to CCDs in 25%. In 29.3%, serum IgE reactivity to any of the cross-reactive components could be demonstrated. Serum IgE reactivity to rBet v 2 was always accompanied by IgE reactivity to rPhl p 12, and IgE reactivity to rBet v 4 was always accompanied by IgE reactivity to rPhl p 7. Among the patients with pollinosis co-sensitized to at least two allergen sources according to extract-based diagnosis, possible false-positive results due to sensitization to cross-reactive components were detected in 17.9%. Conclusion: Evaluation of sensitization to cross-reacting components may be useful in evaluation of patients with pollen allergy who are being assessed for allergen immunotherapy to optimize the constitution of their immunotherapy vaccines.


2013 ◽  
Vol 111 (4) ◽  
pp. 295-297 ◽  
Author(s):  
Antonio Letrán ◽  
Marisa Espinazo ◽  
Francisco Moreno

2012 ◽  
Vol 10 (1) ◽  
Author(s):  
Francesco Marcucci ◽  
Laura Sensi ◽  
Cristoforo Incorvaia ◽  
Ilaria Dell’Albani ◽  
Giuseppe Di Cara ◽  
...  

2018 ◽  
Vol 8 (29) ◽  
pp. 11-15
Author(s):  
Florin-Dan Popescu ◽  
Mariana Vieru

Abstract Clinical entities of food allergy in allergic rhinitis patients due to IgE-sensitization to cross-reactive aeroallergen and food allergen components are well described, but less data are available regarding allergic reactions to foods containing aeroallergens, either due to food contamination, such as oral mite anaphylaxis, or due to their natural presence in the edible products, such as pollen grains in honey and bee products. There are some potential risks for allergic rhinitis subjects due to ingestion of food products containing domestic mite, insect, fungal and pollen allergens. The knowledge of these risks is useful for the allergists and ENT specialists, especially in the context of climate changes with warmer periods facilitating mite growth in flours, and of increase use of phytotherapy and apitherapy products containing pollen grains.


2011 ◽  
Vol 8 (3) ◽  
pp. 31-36
Author(s):  
Marina Valentinovna Manzhos ◽  
E S Fedenko ◽  
M A Myagkova ◽  
G A Keropyan ◽  
S A Shkadov ◽  
...  

Background. The purpose of the work was to investigate remote and preventive results of sublingual allergenspecific immunotherapy (SLiT) at pollinosis patients. Methods. 25 patients at the age from 19 till 50 years old with an allergic rhinitis and asthma (35%) sensitized to artemisia were under the supervision. SLiT was administered in the period since September 2003 till May 2006 with pollen allergen («Sevapharma», Czech Republik). The average total dose of the allergen per one patient at the end of the third year was 189999 PNU. Clinical efficiency was estimated annually and in 30 months after discontinuation of SLiT. Frequency and intensity of symptoms during the pollen season, requirement for medicines, FEV1 parameters and results of prick tests were considered. Results. good and excellent results after three courses of immunotherapy demonstrated 23 patients (92%), satisfactory - 2 patients (8%). The results were remained at 22 patients (88%) within the next 30 months. at 3 patients (12%) increase of rhinoconjunctivitis symptoms was noted, and 3 (12%) showed expansion of a sensibilisation spectrum. Further increase of intensity and frequency of asthma symptoms, decrease in indicators FEV1 was not registered. Conclusion. SLiT is a highly effective method of treatment for patients with seasonal rhinitis and leads to the clinical results remaining more than 2 years at the majority of patients.


Author(s):  
A. Asarnoj ◽  
R. Movérare ◽  
E. Östblom ◽  
M. Poorafshar ◽  
G. Lilja ◽  
...  

2010 ◽  
Vol 71 (9) ◽  
pp. 911-915 ◽  
Author(s):  
Giorgio Ciprandi ◽  
Mara De Amici ◽  
Mariangela Tosca ◽  
Dietmar Fuchs

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Rui Tang ◽  
Jin-Lu Sun ◽  
Jia Yin ◽  
Zhi Li

Artemisiais the most important outdoor allergen throughout China. It can cause allergic rhinitis, asthma, or both of them. Since it was verified as an allergenic pollen in 1960, it was identified two times in the Chinese National Pollen Survey (1984, 2009). The first oral immunotherapy double-blinded trial forArtemisiapollen asthma research was conducted in China in 1989 and published in 1990. 40 years since that study, there have been many published research reports on ChineseArtemisiaallergy. This review summarizes the information regarding the discovery ofArtemisiaas an allergenic pollen, pollen account, epidemiology, allergen components, immunological changes in hay fever patients, natural course from rhinitis to asthma, diagnosis, and immunotherapies in China.


Sign in / Sign up

Export Citation Format

Share Document